GlassScriptPhysician profile
Christopher A Sherman
NPI 1871599555
$3,198.79
in general payments reported to CMS, 2019-2025
30 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,273 · 2020: $464 · 2021: $210 · 2022: $473 · 2023: $191 · 2024: $246 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $779.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $671.17 | 2019-2025 | |
| Abbvie INC. | $481.70 | 2021-2025 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $305.39 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $248.42 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $204.89 | 2019-2021 | |
| Amarin Pharma, INC. | $171.14 | 2019-2022 | |
| Amgen INC. | $136.17 | 2019-2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $126.27 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.36 | 2019-2022 | |
| Lilly USA, LLC | $85.23 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $65.21 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.45 | 2019-2025 | Trintellix |
| Allergan, INC. | $59.30 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $56.08 | 2019-2020 | |
| Exact Sciences Corporation | $50.84 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $48.30 | 2019-2020 | |
| Corium, LLC | $39.89 | 2022-2025 | Azstarys |
| Bausch Health US, LLC | $36.65 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $35.26 | 2021 | |
| Almatica Pharma LLC | $31.24 | 2022 | |
| Optinose US, INC. | $26.35 | 2024 | |
| Sanofi-Aventis U.S. LLC | $25.84 | 2019 | |
| Corcept Therapeutics | $19.18 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.60 | 2019 | |
| Biogen, INC. | $17.25 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.76 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.50 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.42 | 2024 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $14.08 | 2024 | Zoryve |
| Endogastric Solutions, INC | $10.85 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Sherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.